The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Sumarokov A.B.

National Medical Research Centre of Cardiology

Chubykina U.V.

National Medical Research Center of Cardiology

Ezhov M.V.

National Medical Research Center of Cardiology

Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review

Authors:

Sumarokov A.B., Chubykina U.V., Ezhov M.V.

More about the authors

Journal: Russian Cardiology Bulletin. 2022;17(1): 84‑92

DOI: 10.17116/Cardiobulletin20221701184

Read: 81144 times

Download PDF (RU)
Contact the author
Table of contents

RHABDOMYOLYSIS IS A RARE COMPLICATION OF STATIN THERAPY. CASE REPORT AND LITERATURE REVIEW
RHABDOMYOLYSIS IS A RARE COMPLICATION OF STATIN THERAPY. CASE REPORT AND LITERATURE REVIEW

To cite this article:

Sumarokov AB, Chubykina UV, Ezhov MV. Rhabdomyolysis is a rare complication of statin therapy. Case report and literature review. Russian Cardiology Bulletin. 2022;17(1):84‑92. (In Russ.)
https://doi.org/10.17116/Cardiobulletin20221701184

 
ЭндоКард
Подписка 2026 Кардиологический вестник (Russian Cardiology Bulletin)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Pharmacogenetic testing for personalized statin prescription in Moscow. Medi­cal Technologies. Asse­ssment and Choice. 2024;(4):49-55
On the issue of choosing anesthesia methods: a comparison of gene­ral medi­cine and clinical dentistry. Stomatology. 2025;(1):76-80
Bone mine­ral density asse­ssment of women on long-term antiepileptic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):112-116
The influence of demo­graphic factors and major como­rbidities on serum circulating regu­latory microRNAs in patients with coro­nary artery athe­rosclerosis and thoracic aortic aneurysm: a single-center cohort study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):174-182
Recu­rrent coro­nary events as a persistent challenge in cardiology. The role of PCSK9 inhi­bitors in respect of this issue through the example of a local program implemented in St. Pete­rsburg. Russian Journal of Preventive Medi­cine. 2025;(9):78-86
Abstract:

Statins are worldwide medicines for the treatment dyslipidemia accompanying cardiovascular diseases. These drugs are capable to improve cardiovascular prognosis. Serious side effects of statins requiring discontinuation of therapy are rare. Serious side effects of statins include statin-associated muscle symptoms and rhabdomyolysis. The last one is a rare and life-threatening complication. The authors present a patient with statin-induced rhabdomyolysis and modern literature review devoted to this issue.

Keywords:

lipid lowering therapy
statins
side effects
rhabdomyolysis

Authors:

Sumarokov A.B.

National Medical Research Centre of Cardiology

Chubykina U.V.

National Medical Research Center of Cardiology

Ezhov M.V.

National Medical Research Center of Cardiology

Received:

21.01.2022

Accepted:

03.02.2022

Close metadata

References:

  1. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg H. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. European Heart Journal. 2015;36(17):1012-1022. https://doi.org/10.1093/eurheartj/ehv043
  2. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK; American Heart Association Clinical Lipidology, Lipoprotein, Metabolism and Thrombosis Committee, a Joint Committee of the Council on Atherosclerosis, Thrombosis and Vascular Biology and Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Clinical Cardiology; and Stroke Council. Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology. 2019;39(2):38-81.  https://doi.org/10.1161/ATV.0000000000000073
  3. Casula M, Gazzotti M, Bonaiti F, OImastroni E, Arca M, Averna M, Zambon A, Catapano AL; PROSISA Study Group. Reported muscle symptoms during statin treatment amongst Italian dyslipidaemic patients in the real-life setting: the PROSISA Study. Journal of Internal Medicine. 2021;290(1):116-128.  https://doi.org/10.1111/joim.13219
  4. Bruckert E, Hayem G, Dejager S, Yau C, Bégaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovascular Drugs and Therapy. 2005;19(6):403-414.  https://doi.org/10.1007/s10557-005-5686-z
  5. Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics. 2018;15(4):1006-1017. https://doi.org/10.1007/s13311-018-0670-z
  6. Zhang H, Plutzky J, Shubina M, Turchin A. Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study. Annals of Internal Medicine. 2017;167(4):221-227.  https://doi.org/10.7326/M16-0838
  7. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. Journal of General Internal Medicine. 2008;23(8):1182-1186. https://doi.org/10.1007/s11606-008-0636-7
  8. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. Journal of Clinical Lipidology. 2012;6(3):208-215.  https://doi.org/10.1016/j.jacl.2012.03.003
  9. Selva-O’Callaghan A, Alvarado-Cardenas M, Pinal-Fernández I, Trallero-Araguás E, Milisenda JC, Martínez MÁ, Marín A, Labrador-Horrillo M, Juárez C, Grau-Junyent JM. Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Review of Clinical Immunology. 2018;14(3):215-224.  https://doi.org/10.1080/1744666X.2018.1440206
  10. Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R, Carr DF, Bloch KM, Fahy J, Hanson A, Yue QY, Wadelius M, Maitland-van Der Zee AH, Voora D, Psaty BM, Palmer CN, Pirmohamed M. Phenotype standardization for statin-induced myotoxicity. Clinical Pharmacology & Therapeutics. 2014;96(4):470-476.  https://doi.org/10.1038/clpt.2014.121
  11. Thompson PD, Clarkson PM, Rosenson RS; National Lipid Association Statin Safety Task Force Muscle Safety Expert Panel. An assessment of statin safety by muscle experts. American Journal of Cardiology. 2006;97(8A):69C-76C.  https://doi.org/10.1016/j.amjcard.2005.12.013
  12. Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: a case report. Russian Journal of Cardiology. 2021;26(11):4471. (In Russ.). https://doi.org/10.15829/1560-4071-2021-4471
  13. Ezad S, Cheema H, Collins N. Statin-induced rhabdomyolysis: a complication of a commonly overlooked drug interaction. Oxford Medical Case Reports. 2018;2018(3):omx104. https://doi.org/10.1093/omcr/omx104
  14. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-2561. https://doi.org/10.1016/S0140-6736(16)31357-5
  15. Torres PA, Helmstetter JA, Kaye AM, Kaye AD. Rhabdomyolysis: pathogenesis, diagnosis, and treatment. Ochsner Journal. 2015;15(1):58-69. 
  16. Taylor BA, Thompson PD. Statin-Associated Muscle Disease: Advances in Diagnosis and Management. Neurotherapeutics. 2018;15(4):1006-1017. https://doi.org/10.1007/s13311-018-0670-z
  17. Fedorova AA, Kutepov DE, Zubarev AV, Pasechnik IN, Khabarina NV. Phabdomyolysis: what`s new in diagnostic and treatment? Kremliovskaya Meditzina. Klinichesky vestnik. 2020;2:102-109. (In Russ.). https://doi.org/10.26269/4n94-0746
  18. McMahon GM, Zeng X, Waikar SS. A risk prediction score for kidney failure or mortality in rhabdomyolysis. JAMA Internal Medicine. 2013;173(19):1821-1828. https://doi.org/10.1001/jamainternmed.2013.9774
  19. Mancini GB, Tashakkor AY, Baker S, Bergeron J, Fitchett D, Frohlich J, Genest J, Gupta M, Hegele RA, Ng DS, Pearson GJ, Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29(12):1553-1568. https://doi.org/10.1016/j.cjca.2013.09.023
  20. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). Journal of the American College of Cardiology. 2011;57(16):1666-1675. https://doi.org/10.1016/j.jacc.2010.09.082
  21. Ahmad Z. Statin intolerance. American Journal of Cardiology. 2014;113(10):1765-1771. https://doi.org/10.1016/j.amjcard.2014.02.033
  22. Ward NC, Watts CF, Eckel RH. Statin Toxicity/Mechanistic Insights and Clinical Implications. Circulation Research. 2019;124:328-350.  https://doi.org/10.1161/CIRCRESAHA.118.312782
  23. Nguyen KA, Li L, Lu D, Yazdanparast A, Wang L, Kreutz RP, Whipple EC, Schleyer TK. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy. European Journal of Clinical Pharmacology. 2018;74(9):1099-1109. https://doi.org/10.1007/s00228-018-2482-9
  24. Schech S, Graham D, Staffa J, Andrade SE, La Grenade L, Burgess M, Blough D, Stergachis A, Chan KA, Platt R, Shatin D. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiology and Drug Safety. 2007;16(3):352-358.  https://doi.org/10.1002/pds.1287
  25. Thompson PD, Panza G, Zaleski A, Taylor B. Statin-Associated Side Effects. Journal of the American College of Cardiology. 2016;67(20):2395-2410. https://doi.org/10.1016/j.jacc.2016.02.071
  26. Camerino GM, Tarantino N, Canfora I, De Bellis M, Musumeci O, Pierno S. Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence. International Journal of Molecular Sciences. 2021;22(4):2070. https://doi.org/10.3390/ijms22042070
  27. Byler J, Harrison R, Fell LL. Rhabdomyolysis Following Recovery from Severe COVID-19: A Case Report. American Journal of Case Reports. 2021;22:e931616. https://doi.org/10.12659/AJCR.931616
  28. Mendes P, Robles PG, Mathur S. Statin-induced rhabdomyolysis: a comprehensive review of case reports. Physiotherapy Canada. 2014;66(2):124-132.  https://doi.org/10.3138/ptc.2012-65
  29. Guyton JR. Benefit versus risk in statin treatment. American Journal of Cardiology. 2006;97(8A):95C-97C.  https://doi.org/10.1016/j.amjcard.2005.12.016
  30. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289(13):1681-1690. https://doi.org/10.1001.j.jama.289.13.1681
  31. Bubnova M.G. Adverse effects of statin therapy: real evidence. Cardiosomatics. 2019;10(1): 51-61. (In Russ.). https://doi.org/10.26442/22217185.2019.1.190264
  32. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. JAMA Internal Medicine. 2005;165(22):2671-2676. https://doi.org/10.1001/archinte.165.22.2671
  33. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590. https://doi.org/10.1001/jama.292.21.2585
  34. Coste J, Billionnet C, Rudnichi A, Pouchot J, Dray-Spira R, Giral P, Zureik M. Statins for primary prevention and rhabdomyolysis: A nationwide cohort study in France. European Journal of Preventive Cardiology. 2019;26(5):512-521.  https://doi.org/10.1177/2047487318776831
  35. Nance JR, Mammen AL. Diagnostic evaluation of rhabdomyolysis. Muscle Nerve. 2015;51(6):793-810.  https://doi.org/10.1002/mus.24606
  36. Vinci P, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Mearelli F, Biasinutto C, Fiotti N, Di Girolamo FG, Biolo G. Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. International Journal of Molecular Sciences. 2021;22(21):11687. https://doi.org/10.3390/ijms222111687
  37. Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, von Haehling S, Jamialahmadi T, Sahebkar A. Effects of statins on mitochondrial pathways. Journal of Cachexia, Sarcopenia and Muscle. 2021;12(2):237-251.  https://doi.org/10.1002/jcsm.12654
  38. Lotteau S, Ivarsson N, Yang Z, Restagno D, Colyer J, Hopkins P, Weightman A, Himori K, Yamada T, Bruton J, Steele D, Westerblad H, Calaghan S. A Mechanism for Statin-Induced Susceptibility to Myopathy. JACC: Basic to Translational Science. 2019;4(4):509-523.  https://doi.org/10.1016/j.jacbts.2019.03.012
  39. Bouitbir J, Sanvee GM, Panajatovic MV, Singh F, Krähenbühl S. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacological Research. 2020;154:104201. https://doi.org/10.1016/j.phrs.2019.03.010
  40. Ramachandran R, Wierzbicki AS. Statins, Muscle Disease and Mitochondria. Journal of Clinical Medicine. 2017;6(8):75.  https://doi.org/10.3390/jcm6080075
  41. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. Annals of Pharmacotherapy. 2004;38(6):978-981.  https://doi.org/10.1345/aph.1D498
  42. Rabanal-Ruiz Y, Llanos-González E, Alcain FJ. The Use of Coenzyme Q10 in Cardiovascular Diseases. Antioxidants (Basel). 2021;10(5):755.  https://doi.org/10.3390/antiox10050755
  43. Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis. 2015;238(2):329-335.  https://doi.org/10.1016/j.atherosclerosis.2014.12.016
  44. Buettner C, Lecker SH. Molecular basis for statin-induced muscle toxicity: implications and possibilities. Pharmacogenomics. 2008;9(8):1133-1142. https://doi.org/10.2217/14622416.9.8.1133
  45. Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, Casciola-Rosen LA. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63(3):713-721.  https://doi.org/10.1002/art.30156
  46. Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenetics and Genomics. 2006;16(12):873-879.  https://doi.org/10.1097/01.fpc.0000230416.82349.90
  47. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, Maxwell WD, McLeod HL, Krauss RM, Roden DM, Feng Q, Cooper-DeHoff RM, Gong L, Klein TE, Wadelius M, Niemi M. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clinical Pharmacology & Therapeutics. 2014;96(4):423-428.  https://doi.org/10.1038/clpt.2014.125
  48. Arrigoni E, Del Re M, Fidilio L, Fogli S, Danesi R, Di Paolo A. Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins. International Journal of Molecular Sciences. 2017;18(1):104.  https://doi.org/10.3390/ijms18010104
  49. Leonova MV, Gaysenok OV, Leonov AS. Statins pharmacogenetics: metabolizing enzymes and transporters polymorphisms role. Consilium Medicum. 2018;20(10):20-28. (In Russ.). https://doi.org/10.26442/2075-1753_2018.10.20-28
  50. Brunham LR, Baker S, Mammen A, Mancini GBJ, Rosenson RS. Role of genetics in the prediction of statin-associated muscle symptoms and optimization of statin use and adherence. Cardiovascular Research. 2018;114(8):1073-1081. https://doi.org/10.1093/cvr/cvy119
  51. Turner RM, Pirmohamed M. Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. Journal of Clinical Medicine. 2019;9(1):22.  https://doi.org/10.3390/jcm9010022
  52. Ochs-Balcom HM, Nguyen LM, Ma C, Isackson PJ, Luzum JA, Kitzmiller JP, Tarnopolsky M, Weisman M, Christopher-Stine L, Peltier W, Wortmann RL, Vladutiu GD. Clinical features related to statin-associated muscle symptoms. Muscle Nerve. 2019;59(5):537-543.  https://doi.org/10.1002/mus.26397
  53. Kee PS, Chin PKL, Kennedy MA, Maggo SDS. Pharmacogenetics of Statin-Induced Myotoxicity. Front Genet. 2020;11:575678. https://doi.org/10.3389/fgene.2020.575678
  54. Rumyantsev NA, Kukes VG, Kazakov RE, Rumyantsev AA, Sychev DA. Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy. Terapevticheskii Arkhiv. 2017;89(1):82-87. (In Russ.). https://doi.org/10.17116/terarkh201789182-87
  55. Kazakov RE, Evteev VA. Significance of genetic factors in predicting the side effects of statins. International journal of applied and fundamental research. 2016;8:691-698. (In Russ.).
  56. Shulkin AV, Yakusheva EN, Popova NM. The role of p-glycoprotein in rational pharmacotherapy in cardiology. Rational Pharmacotherapy in Cardiology. 2013;9(6):701-707. (In Russ.). https://doi.org/10.20996/1819-6446-2013-9-6-701-707
  57. Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, Hutz MH. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clinical Pharmacology & Therapeutics. 2005;78(5):551-558.  https://doi.org/10.1016/j.clpt.2005.08.003
  58. Hirota T, Ieiri I. Drug-drug interactions that interfere with statin metabolism. Expert Opinion on Drug Metabolism & Toxicology. 2015;11(9):1435-1447. https://doi.org/10.1517/17425255.2015.1056149
  59. Anitha N, Nandagopal A, Unnisa SV, Shireen B, Taslee S. Cytochrome P450 — Role in Drug Metabolism and Genetic Polymorphism. Indo American Journal of Pharmaceutical Sciences. 2018;05(04):2979-2989. https://doi.org/10.5281/zenodo.1231058
  60. Yee J, Kim H, Heo Y, Yoon HY, Song G, Gwak HS. Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis. Journal of Personalized Medicine. 2021;11(7):677.  https://doi.org/10.3390/jpm11070677
  61. SEARCH Collaborative Group, Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R. SLCO1B1 variants and statin-induced myopathy — a genome wide study. New England Journal of Medicine. 2008;359(8):789-799.  https://doi.org/10.1056/NEJMoa0801936
  62. Shuev GN, Sychev DA, Grachev AV. Gene polymorphism SLCO1B1, associated with the development of myopathy in Russian patients with hyperlipidemia using statins. Creative cardiology. 2015;9(4):40-45. (In Russ.). https://doi.org/10.15275/kreatkard.2015.04.05
  63. Sirotkina AM, Khokhlov AL, Voronina EA, Mogutov MS, Dryazhenkova IV, Tsareva IN. et al. Prevalence of the polymorphic marker of the SLCO1B1 gene in patients with dyslipidemia and systemic atherosclerosis. Cardiovascular therapy and prevention. 2013;22. (In Russ.).
  64. Vassy JL, Chun S, Advani S, Ludin SA, Smith JG, Alligood EC. Impact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic Review. Clinical Pharmacology & Therapeutics. 2019;106(2):360-373.  https://doi.org/10.1002/cpt.1223
  65. Melhem AL, Chourasia MK, Bigossi M, Maroteau C, Taylor A, Pola R, Dawed AY, Tornio A, Palmer CNA, Siddiqui MK. Common Statin Intolerance Variants in ABCB1 and LILRB5 Show Synergistic Effects on Statin Response: An Observational Study Using Electronic Health Records. Frontiers in Genetics. 2021;12:713181. https://doi.org/10.3389/fgene.2021.713181
  66. Elam MB, Majumdar G, Mozhui K, Gerling IC, Vera SR, Fish-Trotter H, Williams RW, Childress RD, Raghow R. Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challenge. PLoS One. 2017;12(8):e0181308. https://doi.org/10.1371/journal.pone.0181308
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.